doi:10.3969/j.issn.1004-583X.2024.01.014

Abstract

CLC Number:

R541.6

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.01.014

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I1/75

References 52

[1]	McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36):3599-3726. doi: 10.1093/eurheartj/ehab368 pmid: 34447992
[2]	Barkhudaryan A, Doehner W, Scherbakov N. Ischemic stroke and heart failure: Facts and numbers. An update[J]. J Clin Med, 2021, 10(5):1146. doi: 10.3390/jcm10051146 URL
[3]	Schäfer A, Flierl U, Bauersachs J. Anticoagulants for stroke prevention in heart failure with reduced ejection fraction[J]. Clin Res Cardiol, 2022, 111(1): 1-13. doi: 10.1007/s00392-021-01930-y
[4]	Adelborg K, Szépligeti S, Sundbøll J, et al. Risk of stroke in patients with heart failure: A population-based 30-year cohort study[J]. Stroke, 2017, 48(5):1161-1168. doi: 10.1161/STROKEAHA.116.016022 pmid: 28377383
[5]	Piazza G, Goldhaber SZ, Lessard DM, et al. Venous thromboembolism in heart failure: Preventable deaths during and after hospitalization[J]. Am J Med, 2011, 124(3):252-259. doi: 10.1016/j.amjmed.2010.10.014 pmid: 21396509
[6]	Fanola CL, Norby FL, Shah AM, et al. Incident heart failure and long-term risk for venous thromboembolism[J]. J Am Coll Cardiol, 2020, 75(2):148-158.
[7]	Mongirdiene A, Laukaitiene J, Skipskis V, et al. Platelet activity and its correlation with inflammation and cell count readings in chronic heart failure patients with reduced ejection fraction[J]. Medicina (Kaunas), 2021, 57(2):176.
[8]	Abdo AS, Kemp R, Barham J, et al. Dilated cardiomyopathy and role of antithrombotic therapy[J]. Am J Med Sci, 2010, 339(6):557-560. doi: 10.1097/MAJ.0b013e3181cf048a pmid: 20186041
[9]	Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy[J]. Lancet, 2017, 390(10092):400-414. doi: S0140-6736(16)31713-5 pmid: 28190577
[10]	Jacobson AM, Darrah JR. Biventricular thrombi in substance-induced dilated cardiomyopathy[J]. CASE (Phila), 2020, 4(3):170-174. doi: 10.1016/j.case.2020.01.007 pmid: 32577600
[11]	翟玫, 黄丽燕, 王运红, 等. 扩张型心肌病合并心腔内血栓患者的临床特点分析[J]. 中国循环杂志, 2021, 36(6):563-566.
[12]	Lemaître AI, Picard F, Maurin V, et al. Clinical profile and midterm prognosis of left ventricular thrombus in heart failure[J]. ESC Heart Fail, 2021, 8(2): 1333-1341.
[13]	Zoni-Berisso M, Lercari F, Carazza T, et al. Epidemiology of atrial fibrillation: European perspective[J]. Clin Epidemiol, 2014, 6:213-220. doi: 10.2147/CLEP.S47385 pmid: 24966695
[14]	Ito K, Hongo K, Date T, et al. Tissue thrombin is associated with the pathogenesis of dilated cardiomyopathy[J]. Int J Cardiol, 2017, 228:821-827. doi: S0167-5273(16)33640-3 pmid: 27888761
[15]	Murugesan V, Pulimamidi VK, Rajappa M, et al. Elevated fibrinogen and lowered homocysteine-vitamin determinants and their association with left atrial thrombus in patients with rheumatic mitral stenosis[J]. Br J Biomed Sci, 2015, 72(3):102-106. doi: 10.1080/09674845.2015.11666804 URL
[16]	Topaloglu S, Aras D, Ergun K, et al. Plasma level of soluble P-selectin in patients with rheumatic mitral stenosis and sinus rhythm undergoing percutaneous mitral balloon valvuloplasty[J]. J Thromb Thrombolysis, 2007, 23(3):199-204. doi: 10.1007/s11239-006-9039-y URL
[17]	Aslanabadi N, Separham A, Valae Hiagh L, et al. Association of mean platelet volume with echocardiographic findings in patients with severe rheumatic mitral stenosis[J]. J Cardiovasc Thorac Res, 2019, 11(2):95-99. doi: 10.15171/jcvtr.2019.17 pmid: 31384402
[18]	Goyal A, Aggarwal P, Shrivastava A, et al. Effect of mitral regurgitation on systemic coagulation activity in rheumatic heart disease as assessed by D-dimer levels[J]. Cureus, 2021, 13(9):e17839.
[19]	GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet, 2017, 390(10100):1151-1210. doi: S0140-6736(17)32152-9 pmid: 28919116
[20]	Pang H, Wang L, Liu J, et al. The prevalence and risk factors of venous thromboembolism in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Clin Respir J, 2018, 12(11):2573-2580. doi: 10.1111/crj.12959 pmid: 30207643
[21]	王辰, 杜敏捷, 曹大德. 慢性肺原性心脏病急性发作期肺细小动脉血栓形成的病理观察[J]. 中华医学杂志, 1997, 77(2): 123-125.
[22]	凌刘, 付娟娟. 肝素抗凝治疗对COPD合并肺心病患者凝血及肺动脉压影响的相关性分析[J]. 中华肺部疾病杂志, 2018, 11(4):435-439.
[23]	Yu H, Liu L, Wang J. The relationship between P-selectin on platelet membrane and platelet function in chronic cor pulmonale[J]. Zhonghua Nei Ke Za Zhi, 1995, 34(1):13-15.
[24]	Zheng YG, Yang T, Xiong CM, et al. Platelet distribution width and mean platelet volume in idiopathic pulmonary arterial hypertension[J]. Heart Lung Circ, 2015, 24(6):566-572. doi: 10.1016/j.hlc.2014.11.025 pmid: 25573235
[25]	Uçar H, Gür M, Gözükara MY, et al. Relationship between mean platelet volume and morning blood pressure surge in newly diagnosed hypertensive patients[J]. Anatol J Cardiol, 2015, 15(2):107-112. doi: 10.5152/akd.2014.5196 pmid: 25252294
[26]	Jiang X, Liu X, Liu X, et al. Low-dose aspirin treatment attenuates male rat salt-sensitive hypertension via platelet cyclooxygenase 1 and complement cascade pathway[J]. J Am Heart Assoc, 2020, 9(1):e013470. doi: 10.1161/JAHA.119.013470 URL
[27]	李泽浦, 唐丽萍, 徐兵, 等. 伴高同型半胱氨酸血症的高血压患者血栓前状态的特点及其对远期血栓事件的影响[J]. 中华心血管病杂志, 2015, 4(4):297-303.
[28]	Fujita S, Takeda Y, Kizawa S, et al. Platelet volume indices are associated with systolic and diastolic cardiac dysfunction, and left ventricular hypertrophy[J]. BMC Cardiovasc Disord, 2015, 15:52. doi: 10.1186/s12872-015-0047-8 URL
[29]	Li T, Jin J, Meng Z, et al. The different associations between platelet distribution width and hypertension subtypes in males and females[J]. Biosci Rep, 2020, 40(11):BSR20201747.
[30]	Abdul-Rahim AH, Perez AC, Fulton RL, et al. Risk of stroke in chronic heart failure patients without atrial fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials[J]. Circulation, 2015, 131(17):1486-1494. doi: 10.1161/CIRCULATIONAHA.114.013760 pmid: 25810334
[31]	Freudenberger RS, Hellkamp AS, Halperin JL, et al. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)[J]. Circulation, 2007, 115(20):2637-2641. doi: 10.1161/CIRCULATIONAHA.106.661397 pmid: 17485579
[32]	Hjalmarsson C, Fu M, Zverkova Sandström T, et al. Risk of stroke in patients with heart failure and sinus rhythm: data from the Swedish Heart Failure Registry[J]. ESC Heart Fail, 2021, 8(1):85-94. doi: 10.1002/ehf2.13091 pmid: 33169527
[33]	Lip GY, Ponikowski P, Andreotti F, et al. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis[J]. Eur J Heart Fail, 2012, 14(7):681-695. doi: 10.1093/eurjhf/hfs073 pmid: 22611046
[34]	Tang L, Wu YY, Lip GY, et al. Heart failure and risk of venous thromboembolism: A systematic review and meta-analysis[J]. Lancet Haematol, 2016, 3(1):e30-e44.
[35]	宋倩倩. 重症心力衰竭患者并发房颤的相关因素[J]. 现代诊断与治疗, 2021, 32(22), 3594-3596.
[36]	Pana TA, McLernon DJ, Mamas MA, et al. Individual and combined impact of heart failure and atrial fibrillation on ischemic stroke outcomes[J]. Stroke, 2019, 50(7):1838-1845. doi: 10.1161/STROKEAHA.119.025481 pmid: 31154943
[37]	Lip GY, Laroche C, Popescu MI, et al. Heart failure in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme Pilot survey on atrial fibrillation[J]. Eur J Heart Fail, 2015, 17(6):570-582. doi: 10.1002/ejhf.254 pmid: 25727992
[38]	Mehra MR, Vaduganathan M, Fu M, et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: The COMMANDER HF trial[J]. Eur Heart J, 2019, 40(44):3593-3602. doi: 10.1093/eurheartj/ehz427 pmid: 31461239
[39]	Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease[J]. N Engl J Med, 2017, 377(14):1319-1330. doi: 10.1056/NEJMoa1709118 URL
[40]	Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease[J]. N Engl J Med, 2018, 379(14):1332-1342. doi: 10.1056/NEJMoa1808848 URL
[41]	Melgaard L, Overvad TF, Jensen M, et al. Thromboembolic risk in nonanticoagulated patients with atrial fibrillation and valvular heart disease[J]. JACC Clin Electrophysiol, 2020, 6(13):1672-1682. doi: 10.1016/j.jacep.2020.07.005 pmid: 33334446
[42]	Chung I, Choudhury A, Patel J, et al. Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure[J]. Ann Med, 2009, 41(1):45-51. doi: 10.1080/07853890802227089 pmid: 18618353
[43]	Gibbs CR, Blann AD, Watson RD, et al. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: Effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy[J]. Circulation, 2001, 103(13):1746-1751. pmid: 11282905
[44]	白金祥, 韦建侠. 不同药物治疗老年高血压患者血栓前状态的对比分析[J]. 血栓与止血学, 2020, 26(6): 984-985.
[45]	McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11):993-1004. doi: 10.1056/NEJMoa1409077 URL
[46]	de Peuter OR, Souverein PC, Klungel OH, et al. Non-selective vs. selective beta-blocker treatment and the risk of thrombo-embolic events in patients with heart failure[J]. Eur J Heart Fail, 2011, 13(2):220-226. doi: 10.1093/eurjhf/hfq176 pmid: 20947572
[47]	Schäfer A, Fraccarollo D, Hildemann S, et al. Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition[J]. Thromb Haemost, 2003 ;89(6):1024-1030.
[48]	Gromotowicz-Poplawska A, Kloza M, Aleksiejczuk M, et al. Nitric oxide as a modulator in platelet- and endothelium-dependent antithrombotic effect of eplerenone in diabetic rats[J]. J Physiol Pharmacol, 2019, 70(2). Epub 2019 Jul 22.
[49]	Kim H, Lee K, Choi HA, et al. Elevated blood urea nitrogen/creatinine ratio is associated with venous thromboembolism in patients with acute ischemic stroke[J]. J Korean Neurosurg Soc, 2017, 60(6):620-626. doi: 10.3340/jkns.2016.1010.009 URL
[50]	Elias S, Hoffman R, Saharov G, et al. Dehydration as a possible cause of monthly variation in the incidence of venous thromboembolism[J]. Clin Appl Thromb Hemost, 2016, 22(6):569-574. doi: 10.1177/1076029616649435 URL
[51]	Lowry E. Venous thromboembolism risk with glucocorticoid use[J]. Nurs Times, 2014, 110(6):23. pmid: 24669472
[52]	Stuijver DJF, Majoor CJ, van Zaane B, et al. Use of oral glucocorticoids and the risk of pulmonary embolism: A population-based case-control study[J]. Chest, 2013, 143(5):1337-1342. doi: S0012-3692(13)60332-3 pmid: 23258429

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 52

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Duan Fang, Cui Wei. Application principles of vasodilators in the treatment of acute heart failure [J]. Clinical Focus, 2023, 38(9): 773-778.
[2]	. [J]. Clinical Focus, 2023, 38(9): 832-837.
[3]	. [J]. Clinical Focus, 2023, 38(6): 573-576.
[4]	. [J]. Clinical Focus, 2023, 38(5): 459-464.
[5]	Wang Zhen, Yang Xiaoyue, Li Shaojie, Wang Xian, Chen Shuxia, Gu Jian. Analysis of clinical characteristics and readmission risk factors in patients with ejection fraction preserved heart failure combined with atrial fibrillation [J]. Clinical Focus, 2023, 38(4): 308-314.
[6]	. [J]. Clinical Focus, 2023, 38(4): 369-372.
[7]	Zuo Xiuxiu, Hou Tianhua, Wang Hongxiang. Effect of subclinical hypothyroidism on prognosis of patients with chronic systolic heart failure: A meta-analysis [J]. Clinical Focus, 2022, 37(10): 905-911.
[8]	. [J]. Clinical Focus, 2022, 37(9): 838-841.
[9]	Li Heng, Li Yonghui, Sun Xiaoqiang, Wang Lin, He Feng. Efficacy and safety of anticoagulant therapy for patients with heart failure in sinus rhythm [J]. Clinical Focus, 2022, 37(5): 406-411.
[10]	Luo Fanglin, Guan Suying, Wu Guoxiang. Clinical effect of sacubitril-valsartan combined with activin on acute left heart failure [J]. Clinical Focus, 2021, 36(9): 782-785.
[11]	. [J]. Clinical Focus, 2021, 36(7): 641-645.
[12]	Zhao Meili, Xiao Liyuan, Liu Lin, Kang Chao, Zhang Qiuxiang. Correlation between NT-proBNP, hs-CRP, left atrium diameter and chronic heart failure concurrent with atrial fibrillation [J]. Clinical Focus, 2021, 36(5): 412-415.
[13]	Xu Dongrui, Zhao Qinhui, Liu Tongxiang. Clinical effect of sacubitril/valsartan for heart failure with mid-range ejection fraction in left ventricle [J]. Clinical Focus, 2021, 36(5): 416-420.
[14]	Bai Lian, Guo Peng, Luan Bo, Bai Hao, Jiang Shan. Correlation between serum free fatty acid and cardiac function in patients with acute heart failure [J]. Clinical Focus, 2021, 36(3): 208-211.
[15]	. [J]. Clinical Focus, 2020, 35(12): 1126-1131.